Doctolib \ [fr\]
$6.2Bpaper valuation
// OVERVIEW
Doctolib controls 70% of France's medical appointment infrastructure — which means 45 million French citizens cannot book a GP visit without touching its software, and the French government cannot deploy vaccine campaigns without paying for the privilege. It turned healthcare scheduling into a 30% take-rate SaaS business, convinced French doctors to pay €129/month for software that should have been free public infrastructure, and now faces the question of whether adjacent European markets will accept the same deal before local competitors close the window.
// HQ
Paris, France
// STATUS
PRIVATE
// FOUNDED
2013
// TIER
The Unicorn Herd · $1B – $9.9B
// PRIMARY SECTOR
healthcare it
// FOUNDERS
// FUNDING ROUNDS
// SECTORS SERVED
// TECHNOLOGY
Doctolib runs a three-sided marketplace connecting patients, practitioners, and pharmacies through appointment scheduling, teleconsultation, and practice management software. The core moat is not technical sophistication but network effects compounding with regulatory compliance — French pharmacies and specialists cannot participate in government reimbursement programs without integrating Doctolib's systems, which converts market dominance into structural lock-in. The platform processes 130 million appointments annually across 340,000 practitioners, which generates enough transaction data to build predictive scheduling models competitors cannot replicate without first achieving comparable scale.
// WOWLS ASSESSMENT
Doctolib's €500 million ARR at $6.2 billion valuation implies a 12x revenue multiple, reasonable for a SaaS business with 70% gross margins and demonstrated unit economics — but the growth thesis requires international expansion into Germany and Italy producing comparable penetration rates within 3 years, which is optimistic given that both markets already have entrenched local scheduling platforms and stricter data residency requirements than France. The company raised €500 million at peak European tech valuations in March 2022, then cut 150 staff in 2023 when growth slowed and the Series F multiple looked expensive at the new cost of capital. KKR, Eurazeo, and General Atlantic backed the $6.2 billion round betting that healthcare appointment scheduling would consolidate into natural monopolies per country — a thesis that works in France where Doctolib achieved 70% penetration but has not yet been validated in Germany where it holds 15% share after 4 years and faces Jameda and Samedi as local alternatives. The real risk is that the French moat was built on first-mover advantage during COVID vaccine rollouts when governments needed urgent digital infrastructure and did not negotiate hard — that window has closed and follow-on markets are now building public alternatives rather than accepting vendor lock-in.
// WHY WOWLS HUNTS THIS
Government-dependent SaaS businesses with 70% market share in one country and <20% in adjacent markets are either building a European monopoly or discovering that healthcare sovereignty concerns prevent cross-border scaling. Doctolib has 24 months to prove which one it is before the Series F investors start modeling down-round scenarios.
// VALUATION NOTE
€500M ARR estimate based on March 2022 disclosed figures and subsequent 15-20% reported growth through 2023. Current valuation based on March 2022 Series F round — no public secondary market pricing available to confirm 2024 mark.
VERDICT: DANGEROUS — France paid for a private monopoly when it needed speed and now has 4 years to decide whether to nationalize the infrastructure or accept permanent vendor dependency
// PACK DEBATE
// PACK DEBATE — be the first to weigh in
Google account required — no spam, no nonsense
// LOADING INTEL…
// BROADCAST INTEL
// SIMILAR TARGETS
// INTEL UPDATED: MAY 2026
// INTELLIGENCE DISCLAIMER: Assessments represent editorial opinion based on publicly available data including filings, press reports, and market data as of the date shown. Valuations are approximate. Not financial or investment advice.
// FULL NETWORK ACCESS
🚀 Founder Briefing: Instantly sort investors by Sector, Stage, & Round — direct links to websites for all 1,030 unicorns & backing VCs included.
Don't just track Doctolib \ [fr\].
Master the entire 1,030 unicorn company intelligence network.
Stop analyzing tech monopolies one page at a time. Instantly filter, sort, and isolate the exact venture capital firms, angel investors, and corporate funds backing your specific market vertical. Find investors that fit your sector and deploy your pitch with direct outbound links to every target asset in the database — 1,030 targets total.
Acquire Intel →// 5 TIERS · PAYPAL SECURED
// ENGAGE THE FULL ARSENAL
Done reading on Doctolib \ [fr\]?
Unlock the entire 1,030-company hitlist and 1,030 investor contacts.
Full structural breakdowns. Founder dossiers. VC outreach data. Threat-level intel updated continuously.
→ Deploy 5-Tier Order Form// ARBAN · ZUUN · MINGHAN · TUMEN · KHAN